Chronic Inhibition of 11β-Hydroxysteroid Dehydrogenase Type 1 Activity Decreases Hypertension, Insulin Resistance, and Hypertriglyceridemia in Metabolic Syndrome
Table 2
Renal excretory function in lean and obese SHR-corpulent rats before and after three weeks of treatment with vehicle or compound 11.
Period
Lean SHR-cp vehicle
Lean SHR-cp compound 11
Obese SHR-cp vehicle
Obese SHR-cp compound 11
Urine flow (mL/day)
Baseline
18 ± 1
21 ± 2
57 ± 4#
56 ± 6#
Week 3
24 ± 2
26 ± 3
46 ± 4#
30 ± 4*
Sodium excretion (mmol/day)
Baseline
2.2 ± 0.1
2.3 ± 0.2
3.5 ± 0.2#
3.1 ± 0.2#
Week 3
2.4 ± 0.1
2.0 ± 0.2
3.2 ± 0.3#
2.7 ± 0.3#
Potassium excretion (mmol/day)
Baseline
5.0 ± 0.3
5.1 ± 0.3
8.4 ± 0.3#
8.3 ± 0.3#
Week 3
5.6 ± 0.2
4.8 ± 0.5
8.0 ± 0.6#
Chloride excretion (mmol/day)
Baseline
3.7 ± 0.2
3.7 ± 0.3
5.8 ± 0.2#
5.3 ± 0.3#
Week 3
3.7 ± 0.1
3.1 ± 0.3
5.3 ± 0.5#
4.6 ± 0.2#
Glucose excretion (mg/day)
Baseline
7 ± 2
9 ± 1
3568 ± 391#
3638 ± 538#
Week 3
6 ± 2
4 ± 1
1148 ± 220#
Creatinine clearance (L/day)
Baseline
6.00 ± 0.56
5.86 ± 0.20
5.47 ± 0.35
5.14 ± 0.20
Week 3
6.28 ± 0.60
5.08 ± 0.77
5.95 ± 1.36
5.00 ± 0.23
Microalbumin excretion (mg/day)
Baseline
2 ± 0
1 ± 0
49 ± 15#
50 ± 22#
Week 3
5 ± 1
10 ± 8
85 ± 28#
77 ± 28#
Data are expressed as mean ± SEM. * < 0.05 versus obese SHR-cp vehicle; # < 0.05 versus lean SHR-cp.
